BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
BELITE BIO, INC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$147.34+4.56 (+3.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Belite Bio statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Belite Bio | Industry median |
|---|---|---|
| Market Cap | $5.80B | $166.30M |
| Enterprise Value | $5.44B | $88.19M |
| PB Ratio | 7.52 | 2.03 |
| P/TBV Ratio | 7.52 | 2.29 |
Income (trailing twelve months)
| Measure | Belite Bio | Industry median |
|---|---|---|
| Operating Income | -$84.21M | -$21.40M |
| Pretax Income | -$77.61M | -$14.34M |
| Net Income | -$77.61M | -$22.46M |
| EBITDA | -$84.21M | -$16.91M |
| EPS (Diluted) | -$2.31 | -$0.83 |
Returns
| Measure | Belite Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -16.9% | -53.2% |
| Return on Assets (ROA) | -16.6% | -40.9% |
| Return on Invested Capital (ROIC) | -25.2% | -32.4% |
| Return on Capital Employed (ROCE) | -10.9% | -38.1% |
Balance sheet
| Measure | Belite Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $352.93M | $61.43M |
| Net Cash (Debt) | $352.93M | $15.35M |
| Net Cash Per Share | $8.97 | $0.66 |
| Equity (Book Value) | $770.49M | $49.09M |
| Book Value Per Share | $19.59 | $1.37 |
| Tangible Book Value | $770.47M | $23.52M |
| Working Capital | $484.39M | $76.81M |
Financial position
| Measure | Belite Bio | Industry median |
|---|---|---|
| Current Ratio | 50.02 | 3.34 |
| Quick Ratio | 35.71 | 2.44 |
| Interest Coverage | -42104.00 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Belite Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.99M | -$12.35M |
| Capital Expenditures | -$71.00K | -$1.08M |
| Free Cash Flow | -$37.06M | -$20.22M |
| FCF Per Share | -$0.94 | -$0.42 |
Efficiency
| Measure | Belite Bio | Industry median |
|---|---|---|
| Profits Per Employee | -$155.22K | -$703.34K |
| Employee Count | 500 | 74 |
Dividends and yields
| Measure | Belite Bio | Industry median |
|---|---|---|
| Earnings Yield | -1.34% | -23.3% |
| FCF Yield | -0.64% | -8.72% |
Shares
| Measure | Belite Bio | Industry median |
|---|---|---|
| Shares Outstanding | 39,340,000 | 58,127,000 |
| Shares Change (YoY) | 9.82% | 10.9% |
| Float | 20,927,300 | 49,136,700 |
| Shares Held by Insiders | 46.8% | 11.6% |
| Shares Held by Institutions | 24.1% | 59.4% |
Taxes
| Measure | Belite Bio | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Belite Bio | Industry median |
|---|---|---|
| Altman Z-Score | 345.42 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Belite Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.